Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2001 / Cilt: 27 - Sayı: 4

Effects of chronic renal failure and hemodialysis on serum PSA, free PSA, free/total PSA ratios

Kronik böbrek yetmezliği ve hemodiyalizin serum tPSA, sPSA ve s/tPSA düzeylerine etkisi

Pages
498–502
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum tPSA, fPSA and f/tPS A are reliable parameters in the evaluation of patients in chronic hemodialysis with low-flux membranes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Little is known of the impact of hemodialysis on serum total (tPSA) and free PSA (fPSA) levels.
📊
Key Findings & Data:A total of 46 men under chronic hemodialysis treatment were included. tPSA, fPSA, f/t PSA were measured before and after the dialysis with low-flux membranes in the serum and in the dialysis ultrafiltrate.
💡
Conclusion & Impact:Serum tPSA, fPSA and f/tPS A are reliable parameters in the evaluation of patients in chronic hemodialysis with low-flux membranes.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Böbrek yetmezliği · kronik · Renal diyaliz

Abstract

Little is known of the impact of hemodialysis on serum total (tPSA) and free PSA (fPSA) levels. We prospectively studied the impact of hemodialysis with low-flux membranes on serum tPSA, fPSA and free/total PSA (f/tPSA) ratios. A total of 46 men under chronic hemodialysis treatment were included. tPSA, fPSA, f/t PSA were measured before and after the dialysis with low-flux membranes in the serum and in the dialysis ultrafiltrate. The control group consisted of 216 healthy male individuals. There were no statistically significant difference between the serum levels of tPSA and fPSA in hemodialysis patients and controls (p>0.05 and p>0.05, respectively). However, f/tPSA ratios of hemodialysis patients were significantly higher than those in controls (45.4$\pm$18.1 and 32.12$\pm$16, respectively; p<0.0001). Although, there was a statistically significant increase of mean tPSA and fPSA levels before and after dialysis (before 1.15$\pm$1.0 ng/mL versus 1.4$\pm$1.2 ng/mL; p<0.0001 and before 0.44$\pm$0.29 ng/mL versus 0.54$\pm$0.36 ng/mL; p<0.0001, respectively), there was no statistically significant difference between mean f/tPSA before and after dialysis (before 45.41$\pm$18.1% versus 44.7$\pm$16.5%; p=0.746). Neither tPSA nor fPSA could be shown in the ultrafilrate of any hemodialysis patients. PSA molecules are not eliminated by hemodialysis with low-flux membranes. Serum tPSA, fPSA and f/tPS A are reliable parameters in the evaluation of patients in chronic hemodialysis with low-flux membranes.

Özet

Hemodializin serum total PSA ve serbest PSA düzeylerine etkisi az bilinen bir konudur. Bu çalışmada low-flux membranlarla yapılan hemodiyaliz işleminin serum tPSA, sPSA ve s/tPSA düzeylerine etkisi prospektif olarak değerlendirilmiştir. Kasım 1999 ve Ocak 2000 tarihleri arasında son dönem böbrek yetmezliği sebebiyle kronik diyaliz tedavisi altında bulunan 46 erkek hasta bu çalışmaya dahil edilmiştir. Serum tPSA, sPSA ve s/tPSA düzeyleri low-flux ' membranlarla yapılan hemodiyaliz işleminden hemen önce ve 10 dakika sonra çalışılmıştır. Ayrıca tüm hastaların diyaliz ultrafiltratlarında da tPSA ve sPSA düzeyleri ölçülmüştür. Kontrol grubu, 216 sağlıklı erkek bireyden oluşturulmuştur. Hemodiyaliz hastalarının ve kontrol grubunun serum tPSA ve sPSA değerlerinde istatistiksel olarak anlamlı bir farklılık bulunamamıştır (Sırasıyla p>0.05 ve p>0.05). Fakat s/tPSA değerleri hemodiyaliz hastalarında kontrol grubuna göre daha yüksek bulunmuştur (Sırasıyla 45.4$\pm$18.1 ve 32.12$\pm$16; p<0.0001). Ortalama tPSA ve sPSA değerlerinde hemodiyaliz sonrasında, hemodiyaliz öncesine göre istatistiksel olarak anlamlı bir artış bulunurken (Sırasıyla; hemodiyaliz öncesi 1.15$\pm$1.0 ng/mL sonrası 1.4$\pm$1.2 ng/mL; p<0.0001 ve hemodiyaliz öncesi 0.44$\pm$0.29 ng/mL sonrası 0.54$\pm$0.36 ng/mL; p<0.0001), f/t PSA değerlerinde hemodiyaliz öncesi ve sonrasında istatistiksel olarak anlamlı bir farklılık bulunamamıştır (Hemodiyaliz öncesi %45.41$\pm$18.1 sonrası %44.7$\pm$16.5; p=0.746). Hemodiyaliz ultrafiltratlarında hem tPSA hem de sPSA gösterilememiştir. PSA molekülleri low-flux membranlarla yapılan hemodiyaliz işleminde elimine olmamaktadır. Diyaliz sonrası olan serum PSA artışlarının hastaların değerlendirilmesini etkilemediği ve hemokonsantrasyona bağlı olabileceği sonucuna varılmıştır. tPSA, sPSA ve s/tPSA low-flux membranlarla diyalize giren hastalarda kullanılabilecek güvenli parametrelerdir.

🔖

Cite This Article

ÖZER, G., KOÇAK, B., ALTINEL, M., ALTAN, Ş. A., GÖNENÇ, F. (2001). Effects of chronic renal failure and hemodialysis on serum PSA, free PSA, free/total PSA ratios. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 27 - Sayı: 4, 498–502. https://ajindex.com/articles/328611

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Catalona WJ, Smith DS, Ratliff TL, Dodds AM, Coplen DE, Wuan JJ, Petros JA, Andrio-le GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 324: 1156-61, 1991 2- Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB: Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA. 274: 1214-20, 1995 3- Brawer MK: Prostate-specific antigen: Critical issues. Urology. 44(6A): 9-17, 1994 4- Lindner A, Farewell VT, Sherrad DJ: High in-cidence of neoplasia in uremic patients receiving long-term dialysis. Nephron. 27: 292-96, 1981 5- Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics 1997. CA Cancer J Clin. 47: 5-27, 1997 6- Hodge KK, McNeal JE, Terris MK, Stamey TA: Random systematic versus directed ultraso-und-guided transrectal core biopsies of the pros-tate. J Urol. 142: 71-5, 1989 7- Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate-specific antigen. Invest Urol. 17: 159-63, 1979 8- Lilja H: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest. 76: 1899, 1985 9- Watt KWK, Lee PJ, M’Timkulu T, Chan WP, Loor R: Human prostate-specific antigen: Struc-tural and functional similarity with serine protea-ses. Proc Natl Acad Sci. 88: 3166, 1986 10- Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a marker for adenocarcinoma of the prostate. N Engl J Med. 317: 909-16, 1987 11- Stenman UH, Leinonen J, Alfthan H, Rannik-ko S, Tuhkanen K, Alfthan O: A complex bet-ween prostate-specific antigen and alpha 1-anti-chymotrypsin is the major form of prostate-spe-cific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51: 222-6, 1991 12- Lilja H, Christensson A, Dahlen U, Matikai-nen M, Nilsson O, Petterson K, Lovgren T: Prostate-specific antigen in serum occurs predo-minantly in complex with alpha 1-antichymo-trypsin. Clin Chem. 37: 1618- 25, 1991 13- Kabalin JN, Hornberger JC: Prostate-specific antigen is not excreted by human kidney or eli-minated by routine hemodialysis. Urology. 37: 308-10, 1991 14- Morton JJ, Howe SF, Lowell JA, Stratta RJ, Taylor RJ: Influence of end stage renal disease and renal transplantation on serum prostate spe-cific antigen. Br J Urol. 75: 498-501, 1995 15- Lye WC, Tambyah P, Leong SO, Lee EJ: Se